OBJECTIVE: Adenosine A(2A) receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A(2A) receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. METHODS: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A(2A) receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. RESULTS: ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-alpha, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. CONCLUSIONS: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A(2A) receptors on CD4+ T cells and neutrophils. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
OBJECTIVE:Adenosine A(2A) receptor activation potently attenuates lung ischemia-reperfusion injury. This study tests the hypothesis that adenosine A(2A) receptor activation attenuates ischemia-reperfusion injury by inhibiting CD4+ T cell activation and subsequent neutrophil infiltration. METHODS: An in vivo model of lung ischemia-reperfusion injury was used. C57BL/6 mice were assigned to either sham group (left thoracotomy) or 7 study groups that underwent ischemia-reperfusion (1 hour of left hilar occlusion plus 2 hours of reperfusion). ATL313, a selective adenosine A(2A) receptor agonist, was administered 5 minutes before reperfusion with or without antibody depletion of neutrophils or CD4+ T cells. After reperfusion, the following was measured: pulmonary function using an isolated, buffer-perfused lung system, T cell infiltration by immunohistochemistry, myeloperoxidase and proinflammatory cytokine/chemokine levels in bronchoalveolar lavage fluid, lung wet/dry weight, and microvascular permeability. RESULTS:ATL313 significantly improved pulmonary function and reduced edema and microvascular permeability after ischemia-reperfusion compared with control. Immunohistochemistry and myeloperoxidase content demonstrated significantly reduced infiltration of neutrophils and CD4+ T cells after ischemia-reperfusion in ATL313-treated mice. Although CD4+ T cell-depleted and neutrophil-depleted mice displayed significantly reduced lung injury, no additional protection occurred when ATL313 was administered to these mice. Expression of tumor necrosis factor-alpha, interleukin 17, KC, monocyte chemotactic protein-1, macrophage inflammatory protein-1, and RANTES were significantly reduced in neutrophil- and CD4+ T cell-depleted mice and reduced further by ATL313 only in neutrophil-depleted mice. CONCLUSIONS: These results demonstrate that CD4+ T cells play a key role in mediating lung inflammation after ischemia-reperfusion. ATL313 likely exerts its protective effect largely through activation of adenosine A(2A) receptors on CD4+ T cells and neutrophils. 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Authors: S M Fiser; C G Tribble; S M Long; A K Kaza; J T Cope; V E Laubach; J A Kern; I L Kron Journal: J Thorac Cardiovasc Surg Date: 2001-06 Impact factor: 5.209
Authors: Yuan-Ji Day; Liping Huang; Marcia J McDuffie; Diane L Rosin; Hong Ye; Jiang-Fan Chen; Michael A Schwarzschild; J Stephen Fink; Joel Linden; Mark D Okusa Journal: J Clin Invest Date: 2003-09 Impact factor: 14.808
Authors: Marc de Perrot; Kevin Young; Yumiko Imai; Mingyao Liu; Thomas K Waddell; Stefan Fischer; Li Zhang; Shaf Keshavjee Journal: J Immunol Date: 2003-11-15 Impact factor: 5.422
Authors: Zequan Yang; Ashish K Sharma; Joel Linden; Irving L Kron; Victor E Laubach Journal: J Thorac Cardiovasc Surg Date: 2009-03 Impact factor: 5.209
Authors: Tobias Eckle; Emily M Kewley; Kelley S Brodsky; Eunyoung Tak; Stephanie Bonney; Merit Gobel; Devon Anderson; Louise E Glover; Ann K Riegel; Sean P Colgan; Holger K Eltzschig Journal: J Immunol Date: 2014-01-03 Impact factor: 5.422
Authors: Daniel P Mulloy; Ashish K Sharma; Lucas G Fernandez; Yunge Zhao; Christine L Lau; Irving L Kron; Victor E Laubach Journal: Ann Thorac Surg Date: 2013-03-28 Impact factor: 4.330
Authors: Abbas Emaminia; Damien J Lapar; Yunge Zhao; John F Steidle; David A Harris; Victor E Laubach; Joel Linden; Irving L Kron; Christine L Lau Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: Eric J Charles; J Hunter Mehaffey; Ashish K Sharma; Yunge Zhao; Mark H Stoler; James M Isbell; Christine L Lau; Curtis G Tribble; Victor E Laubach; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2017-04-12 Impact factor: 5.209
Authors: Damien J LaPar; Victor E Laubach; Abbas Emaminia; Ivan K Crosby; Vanessa A Hajzus; Ashish K Sharma; Heather M Sumner; David V Webb; Christine L Lau; Irving L Kron Journal: J Thorac Cardiovasc Surg Date: 2011-07-16 Impact factor: 5.209